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ARTICLE
Mutations in CABP4, the Gene Encoding the Ca2+-Binding Protein
4, Cause Autosomal Recessive Night Blindness
Christina Zeitz, Barbara Kloeckener-Gruissem, Ursula Forster, Susanne Kohl, Istva´n Magyar,
Bernd Wissinger, Ga´bor Ma´tya´s, Franc¸ois-Xavier Borruat, Daniel F. Schorderet, Eberhart Zrenner,
Francis L. Munier, and Wolfgang Berger
Mutations in genes encoding either components of the phototransduction cascade or proteins presumably involved in
signaling from photoreceptors to adjacent second-order neurons have been shown to cause congenital stationary night
blindness (CSNB). Sequence alterations in CACNA1F lead to the incomplete type of CSNB (CSNB2), which can be dis-
tinguished by standard electroretinography (ERG). CSNB2 is associated with a reduced rod b-wave, a substantially reduced
cone a-wave, and a reduced 30-Hz ﬂicker ERG response. CACNA1F encodes the a1-subunit of an L-type Ca
2+ channel
(Cav1.4a), which is speciﬁc to photoreceptors and is present at high density in the synaptic terminals. Ten of our patients
with CSNB2 showed no mutation in CACNA1F. To identify the disease-causing mutations, we used a candidate-gene
approach. CABP4, a member of the calcium-binding protein (CABP) family, is located in photoreceptor synaptic terminals
and is directly associated with the C-terminal domain of the Cav1.4a. Mice lacking either Cabp4 or Cav1.4a display a
CSNB2-like phenotype. Here, we report for the ﬁrst time that mutations in CABP4 lead to autosomal recessive CSNB.
Our studies revealed homozygous and compound heterozygous mutations in two families. We also show that these
mutations reduce the transcript levels to 30%–40% of those in controls. This suggests that the reduced amount of CABP4
is the reason for the signaling defect in these patients.
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Mutations in genes encoding either different components
of the phototransduction cascade (RHO [MIM 180380],
GNAT1 [MIM 139330], PDE6B [MIM 163500], GRK1 [MIM
180381], and SAG [MIM 181031]) or proteins presumably
involved in signaling from photoreceptors to adjacent sec-
ond-order neurons (CACNA1F [MIM 300110], NYX [MIM
300278], and GRM6 [MIM 604096]) have been shown to
cause congenital stationary night blindness (CSNB), a
nonprogressive retinal disorder characterized by impaired
night vision and other ocular symptoms such as myopia,
hyperopia, nystagmus, and reduced visual acuity (VA).1–21
The different forms of CSNB can be classiﬁed as shown in
ﬁgure 1. Only a few mutations have been described for
autosomal dominant and recessive forms with fundus ab-
normalities, whereas most mutations have been identiﬁed
in X-linked cases. The X-linked inherited CSNB (XLCSNB)
can be divided into two types: a complete form (cCSNB),
CSNB1 (MIM 310500), and an incomplete form (icCSNB),
CSNB2 (MIM 300071). These two subtypes can be diag-
nosed by electroretinography (ERG) and by molecular
means.22,23 CSNB2 is associated with a reduced rod b-wave,
a substantially reduced cone a-wave, and a reduced 30-Hz
ﬂicker ERG response, whereas the oscillatory potentials are
normal. The disease is associated with mutations in the
CACNA1F gene.8,9 In contrast, CSNB1 is characterized by
a complete loss of rod b-wave and oscillatory potentials
and by largely normal cone a-wave amplitudes, and it is
caused by mutations in NYX.10,11 Recently, three families
were found to carry mutations in GRM6, the gene encod-
ing the metabotopic glutamate receptor 6 (mGluR6).
These mutations lead to an autosomal recessive (ar) form
of CSNB (arCSNB), whose clinical phenotype is very sim-
ilar to that of CSNB1, but the scotopic 15-Hz ﬂicker ERG
shows a distinct signal in the rod pathway.20
When routine screening is performed for CSNB for all
known genes associated with this disorder, a certain per-
centage of cases remain unresolved, which indicates the
large degree of genetic heterogeneity in CSNB. These un-
resolved cases prompted us to use a candidate-gene ap-
proach, to search for additional factors that may cause the
CSNB phenotype. CACNA1F encodes the a1-subunit of an
L-type Ca2 channel (Cav1.4a), which is speciﬁc to pho-
toreceptors and is present at high density in the synaptic
terminals.24,25 The Ca2 inﬂux through Cav1.4 channels
triggers the continuous release of glutamate from the pho-
toreceptor synapse in the dark.26,27 CABPs are neuronal
Ca2-binding proteins with similarity to calmodulin and
have been shown to modulate voltage-dependent Ca2
channels.28,29 CABP4 (MIM 608965) is one member of this
family and, like Cav1.4a, is speciﬁcally located in pho-
toreceptor synaptic terminals. It is directly associated
with the C-terminal domain of Cav1.4a and shifts the
activation of Cav1.4 to hyperpolarized voltages in trans-
fected cells.29 CABP4 consists of 275 aa encoded by six
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Figure 1. The different forms of human CSNB are classiﬁed according to their mode of inheritance, phenotype, and mutated genes.
ad p Autosomal dominant; ar p autosomal recessive; cCSNB p complete CSNB; icCSNB p incomplete CSNB. Genes are indicated in
italics and are underlined. Chromosomal location is given in parentheses.
exons of the CABP4 gene (GenBank accession number
NM_145200), which is located on chromosome 11q13.1.
Mice lacking Cabp4 showed a thinner outer plexiform
layer (OPL), which, in wild-type mice, contains the syn-
apses between the photoreceptor and secondary neurons.
In addition, Cabp4/ retinae also revealed ectopic synapses
originating from rod bipolar and horizontal cells that ex-
tended into the outer nuclear layer (ONL). ERG studies in-
dicated a reduction in cone and rod synaptic function.30
Recently, similar morphological and functional alterations
have been observed in the retina ofCacna1f-mutantmice.31
These studies rendered CABP4 an attractive candidate for
arCSNB. Here, we report on the identiﬁcation of muta-
tions in CABP4 in two families that are indicative for
CSNB2, according to clinical examinations.
Subjects and Methods
Patients
Three patients from two unrelated families were investigated clin-
ically and genetically in this study. Genetic studies were also per-
formed in other unaffected family members. Patients and their
family members were seen either at the Jules Gonin Eye Hospital
in Lausanne, Switzerland, or at the Department for Pathophysi-
ology of Vision and Neuroophthalmology, University Eye Hos-
pital, in Tuebingen, Germany. Written informed consent for mo-
lecular genetic testing was obtained from all patients and family
members. The study was approved by the ethical committees of
the respective institutions. Ophthalmic examination included
evaluation of best-corrected VA, kinetic Goldmann perimetry,
slit-lamp examination, funduscopy, and ocular coherence to-
mography; full-ﬁeld ERG was performed in accordance with In-
ternational Society for Clinical Electrophysiology of Vision
(ISCEV) standards, in both scotopic and photopic conditions.32
Mutation Analysis
We isolated genomic DNA from peripheral blood by standard
techniques, using the chemagic Magnetic Separation Module I
(Chemagen), the Nucleon extraction kit (AmershamBiosciences),
or the manual salting-out procedure.33 All 48 exons of the
CACNA1F gene were analyzed for mutations, as described else-
where.18 Four fragments that cover the six coding exons ofCABP4
were PCR ampliﬁed with intronic or exonic primers and were
sequenced with the appropriate primers (table 1). Buffer condi-
tions for ampliﬁcation and sequencing of CABP4 were similar to
those used for the characterization of GRM6.20 The control panel
included 1210 alleles from unrelated unaffected individuals.34
In Silico Analysis
To assess the potential impact of an amino acid substitution on
the function of the protein, we used two sequence homology–
based programs, Sort Intolerant from Tolerant (SIFT) and Poly-
morphism Phenotype (PolyPhen). To predict a possible disruption
of the calcium-binding EF motif and a posttranslational modiﬁ-
cation due to the amino acid change or protein elongation, we
used ExPASy. Potential splice–donor/acceptor sequence motifs
present in reference and mutant genomic sequences were
searched by the use of NNSPLICE software35 (BerkeleyDrosophilia
Genome Project). To predict possible exon-splicing–enhancer
binding sites, we used the Web-based tool ESEﬁnder.
Expression Analysis of CABP4
Venous blood samples from patients, selected family members,
and controls were collected in PAXgene tubes. Total RNA was
isolated using a commercially available kit (PAXgene Blood RNA
kit [Qiagen]) and was processed as described elsewhere.36 Specif-
ically, all blood samples but one were processed within 5 d after
storage at ambient temperature. One sample (II-1 from family B)
was additionally stored at 20C after 5 d storage at room tem-
perature, and thawing procedures speciﬁed by the manufacturer
were followed. For qualitative and quantitative RT-PCR experi-
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Table 1. PCR Conditions and Primers Used for the Ampliﬁcation, Sequencing, and Expression Study of CABP4
Primer Name
Primer Sequence
Annealing
Temperature
(C)
Fragment
Size
(bp)Forward Reverse
CABP4_1 5′-CCTAGGCTCTCAGCTCTAAG-3′ 5′-CCAAACCGCAGCAACCCTG-3′ 60 622
CABP4_2_3 5′-CCAACATGAGCAGGGGATG-3′ 5′-GAGAGGCAGGAGCTTGAAC-3′ 58 495
CABP4_4 5′-GTGTTTCTTCCTAGGTGCAG-3′ 5′-GATCTGAACCATCTCTGACC-3′ 58 372
CABP4_5_6 5′-AAAAGAGTGGAGCTGGCTGA-3′ 5′-GATAGAAGTAGTCTGGGGGC-3′ 60 483
RT_CABP4_Exon1_For and RT_CABP4_Exon4_Rev 5′-GTTGTGACTCCCAAGAGTGA-3′ 5′-CTCAGCTTTGGGCCTATCAG-3′ 62 524
RT_CABP4_Exon2_For and RT_CABP4_Exon4_Rev 5′-GAACTGGGCCCCGAGGAG-3′ 5′-CTCAGCTTTGGGCCTATCAG-3′ 60 224
RT_CABP4_Exon2_For and RT_CABP4_Exon6_Rev 5′-GAACTGGGCCCCGAGGAG-3′ 5′-GATAGAAGTAGTCTGGGGGC-3′ 62 581
RT_CSPG2_Exon6_For and RT_CSPG2_Exon9_Rev 5′-GGTGGTCTACTTGGGGTGAG-3′ 5′-TCACACTGGTCTCCGCTGTA-3′ 60 208
ments, randomly primed cDNA was generated from 1 mg total
RNA with the use of Superscript III (Invitrogen), as well as the
High Capacity cDNA Archive kit (Applied Biosystems). RT-PCR
experiments were performed using HotStarTaq Polymerase (Qia-
gen) in the presence of 1.5 mM MgCl2 and Q-solution (Qiagen),
with primers in exons 2 and 4 or in exons 2 and 6 for CABP4
and in exons 6 and 9 for CSPG2 (table 1).
Quantitative TaqMan analysis was performed using an assay-
on-demand probe (Hs00376966_m1 [Applied Biosystems]) on an
ABI 7900 HT sequence detection system. 18S rRNA served as en-
dogenous control.37 For each RNA sample, three independent re-
verse-transcription reactions were performed, and seven serial di-
lutions were generated to cover a concentration range of 80–0.62
ng/ml, followed by eight more dilutions ranging from208 to 0.095
pg/ml. From a control sample, 2-ml aliquots of each dilution step
were used to establish a standard curve. For patient and control
samples, we chose two different concentrations (40 and 20 ng/
ml) to assay CABP4 and one concentration (40 pg/ml) to assay the
endogenous control, 18S rRNA, in a reaction volume of 15 ml.
Ampliﬁcation conditions suggested in the standard protocol from
the company (Applied Biosystems) were used. Quantiﬁcationwas
based on the standard-curve method described elsewhere (User
Bulletin #2 [Applied Biosystems]). Together, the three different
reverse-transcriptase reactions, each tested with two different di-
lutions in ﬁve separate replicates, represent the bases for the sta-
tistical analysis.
RT-PCR products of CABP4 cDNA ampliﬁed with primers in
exons 2 and 6 were cloned in a commercially available vector
(pCR2.1-TOPO [Invitrogen]) and were sequenced with standard
M13 primers. The presence of allele-speciﬁc transcripts was as-
sessed by sequencing the appropriate RT-PCR products on an ABI
PRISM 3100 Genetic Analyzer, with the use of the BigDye Ter-
minator v1.1 cycle sequencing kit (Applied Biosystems) and prim-
ers RT_CABP4_Exon1_For and RT_CABP4_Exon4_Rev. Before se-
quencing, RT-PCR products were puriﬁed by the ExoSAP-IT
clean-up method (USB Corporation).
Results
Clinical Characteristics
Family A.—Family A consists of the index patient (II-5),
an affected brother (II-6), four unaffected siblings, and
their unaffected parents (ﬁg. 2A). To our knowledge, the
parents are not consanguineous. The family history was
negative for CSNB. The two patients presented nystagmus
and decreased VA in early childhood. In both patients at
age 15 years, best-corrected VA was 20/100 in both eyes.
The disease course in the index patient (II-5) was station-
ary for 30 years. Yet, he recently experienced a decrease
in VA. Neither patient complained about night blindness,
and only patient II-5 had recently developed moderate
photophobia accompanied by a mild decrease in VA.
Patient II-5 was 39 years old at the time of this recent
examination (in 2005). VA had decreased to 20/200 in
both eyes, and the peripheral visual ﬁeld was moderately
constricted (Goldmann kinetic perimetry with size V4e
stimulus), with a marked decrease in central sensitivity in
both eyes. Results of slit-lamp tests were unremarkable.
Results of fundus examination were noticeable for an ab-
sent foveal reﬂex but were otherwise normal. Autoﬂuoresc-
ence of the macula was absent, and results of ﬂuorescein
angiography were unremarkable. Results of full-ﬁeld sco-
topic ERG were markedly abnormal (ﬁg. 3).With the ISCEV
standard ﬂash attenuated by 24 dB, the rod b-wave am-
plitude was moderately reduced, with a marked prolon-
gation of the implicit time (ﬁg. 3A). With the use of the
unattenuated ISCEV standard ﬂash, the amplitude and im-
plicit time of the a-wave were normal, but the b-wave
remained “negative,” never reaching baseline (b/a–wave
ratio 0.5; normal 11.4) (ﬁg. 3B). Under photopic condi-
tions, the b-wave amplitude was moderately to severely
reduced, with a slightly delayed implicit time (ﬁg. 3C).
Photopic 30-Hz ﬂicker stimulus revealed a decreased am-
plitude with normal implicit time in both patients (ﬁg.
3D).
Patient II-6 was 45 years old when recently examined
(in 2005). His clinical presentation was similar to that of
his younger brother, but without a recent onset of pho-
tophobia. VA was 20/200 in the right eye and 20/400 in
the left eye. Peripheral visual ﬁelds (Goldmann kinetic
perimetry with size V4e stimulus) were preserved, with a
marked decrease in central sensitivity. Results of slit-lamp
and fundus examinations were unremarkable. Results of
full-ﬁeld ERG (ﬁg. 3) were slightly better (i.e., bigger am-
plitudes and less-delayed implicit times) than those of his
younger brother.
Family B.—Family B consists of the affected index patient
(II-1), his unaffected brother, and the unaffected parents
(ﬁg. 2B). The index patient was investigated at age 15
years, to clarify the progressive reduction of his VA. He
reported reduced VA and night blindness. The family his-
tory was negative for CSNB. Besides microstrabismus div-
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Figure 2. Pedigrees of two families with arCSNB and segregating mutations. A, Pedigree of family A. B, Pedigree of family B. Circles
indicate females, squares indicate males, open symbols indicate unaffected individuals, semiﬁlled symbols indicate carriers, and ﬁlled
symbols indicate affected individuals. Generations and individuals are identiﬁed by roman and arabic numerals, respectively. The
determined genotype is given below each symbol. C, Electropherograms showing two different CABP4 mutations. Arrows indicate the
site of mutation. Patients II-5 and II-6 of family A were homozygous for c.800_801delAG, whereas patient II-1 of family B was compound
heterozygous for the missense mutation c.370CrT and for the c.800_801delAG deletion. Lowercase letters indicate intronic sequences,
and uppercase letters indicate exonic sequences.
ergens, there was no abnormality of eye movements. VA
was decreased to 20/30 in both eyes. Automated static
perimetry (30) revealed only very mild relative defects
throughout the visual ﬁeld with normal central thresh-
olds. Results of slit-lamp examination were unremarkable.
The fundus showed no pathological ﬁndings. Macula re-
ﬂexes were present. Dark-adaptation threshold after 30
min was elevated by 1 log unit. The panel D15 vision test
under saturated conditions resulted in confusions on the
tetartan axis in the right eye, whereas no confusions were
found in the left eye. Under desaturated conditions, both
eyes exhibited numerous confusions in the scotopic axis.
Full-ﬁeld ERG revealed anomalies of both rod and cone
systems (ﬁg. 3E). The rod b-wave amplitude, elicited by a
white ISCEV standard ﬂash attenuated by 24 dB, was !20%
of the normal mean, with slightly prolonged latencies.
The maximum response, elicited by the ISCEV standard
ﬂash, was dominated by a normal a-wave amplitude and
implicit time with markedly reduced b-wave (b/a–wave
ratio !0.6; normal values 11.4) (ﬁg. 3E). The oscillatory
potentials could not be separated. The single ﬂash cone
b-wave response was just outside the lower-norm ampli-
tude, with markedly prolonged implicit time. The 30-Hz
ﬂicker ERG amplitude was only ∼10% of the normalmean
(ﬁg. 3E). This pattern of ERG is typical for CSNB in general,
with a well-developed a-wave but a minimal b-wave. Mul-
tifocal ERG studies in this patient revealed that the re-
sponses were recordable in all rings up to 40 excentricity,
www.ajhg.org The American Journal of Human Genetics Volume 79 October 2006 661
yet amplitudes were markedly reduced to ∼50% of normal
values.
Mutation Screening and Expression Analysis
By clinical examination, patients in family A were cate-
gorized as suffering from CSNB2 (ﬁg. 2A). The index pa-
tient (II-5) and one brother (II-6) showed a phenotype
typically observed in patients carrying mutations in
CACNA1F (ﬁg. 3A–3D). However, mutation screening was
negative for this gene. On the basis of its cellular colo-
calization and functional interaction with the Cav1.4a
channel, we considered CABP4 a good candidate gene.
We screened genomic DNA from all family members by
DNA sequence analysis of the ORF of the six exons and
ﬂanking intronic sequences of CABP4. In the two affected
male patients, a homozygous deletion (c.800_801delAG)
of two nucleotides was identiﬁed (for transcript analysis,
see below) (family A in ﬁg. 2C). Two potential conse-
quences of this c.800_801delAG mutation can be envi-
sioned: (i) a translational frameshift, p.Glu267fs, that gives
rise to an elongated protein with 91 additional novel
amino acid residues (ﬁg. 4) and (ii) an effect on the splicing
efﬁciency.
Segregation analysis in family A showed that the un-
affected parents (I-1 and I-2), two unaffected sisters (II-1
and II-2), and one unaffected brother (II-3) were hetero-
zygous for this mutation, whereas the second unaffected
brother (II-4) showed two normal alleles (ﬁg. 2A). None
of 216 control alleles showed this deletion.
These results prompted us to analyze the DNA of 32
additional patients with CSNB: 14 patients with uncertain
CSNB-type assignment and 18 patients with CSNB2, of
whom only 9 had been excluded for mutations in
CACNA1F (data not shown). One patient (II-1 from family
B) from the group in which CACNA1F had not yet been
examined was found to carry two heterozygous alter-
ations in the CABP4 gene (family B in ﬁg. 2B). One allele
showed a c.370CrT substitution in exon 2, which may
introduce a binding site for SRp55, inﬂuencing splicing
(Web-based ESEﬁnder), or may lead to an amino acid ex-
change (p.Arg124Cys). None of 228 control alleles
showed this deletion. The other allele carried the same
c.800_801delAG deletion observed in family A (ﬁgs. 2B,
2C, and 4). On the basis of conservation of sequence ho-
mologies, PolyPhen and SIFT predicted p.Arg124Cys as
“functional damaging,” by scores of 2.495 and 0.00, re-
spectively. Results of PolyPhen are reported as “benign”
(!0.5), “possibly damaging” or “probably damaging” (0.5–
2), “probably damaging” (12), or “unknown.” Scores de-
pend on the sequences and 3D models available and thus
may vary. In SIFT, the results are described as “tolerated”
(10.05) or “affect protein function” (!0.05). None of 210
control alleles showed the c.370CrT substitution. Seg-
regation analysis provided evidence that the father of this
patient was heterozygous for the deletion, whereas the
mother was heterozygous for the missense mutation. The
unaffected brother (II-2) carried no mutation (ﬁg. 2B).
The c.800_801delAG mutation occurred on the same
haplotype for two SNPs in intron 3 in both parents of
family A. Consequently, a common origin of these alleles
is possible: (1) for rs1638564 (c.5417GrC): I-1, G/G; I-
2, G/C; II-1, G/C; II-2, G/C; II-3, G/G; II-4, G/C; II-5, G/
G; II-6, G/G; and (2) for rs1638564 (c.5418ArC): I-1, C/
C; I-2, C/A; II-1, C/A; II-2, C/A; II-3, C/C; II-4, C/A; II-5,
C/C; II-6, C/C. Family B reported that the father‘s family,
which carries the c.800_801delAG mutation, immigrated
from Switzerland 2 generations previously, which is also
where family A originates. Indeed, the c.800_801delAG
deletion in family B also occurred on the same haplotype:
(1) for rs163864 (c.5417GrC): I-1, G/C; I-2, G/C; II-1,
G/G; II-2, C/C; and (2) for rs1638565 (c.5418ArC): I-1,
C/A; I-2, C/A; II-1, C/C; II-2, A/A. Consequently, a com-
mon origin of this mutation in the two families is possible.
Thus, we identiﬁed mutations in CABP4 in one family
with CSNB (family A) previously excluded from the anal-
ysis of CACNA1F and in a second family (family B) not
yet analyzed.
To exclude the possibility of a CACNA1F mutation in
family B, we performed mutation analysis in the index
patient (II-1) of this family (ﬁg. 2B). This analysis revealed
a hemizygous c.2204ArC (AACrACC) transversion in
exon 16, which is predicted to lead to a p.Asn735Thr
amino acid substitution. PolyPhen and SIFT predicted this
sequence variant as possibly damaging, by scores of 1.35
and 0.01, respectively. None of 242 control alleles showed
this substitution. However, the unaffected brother (II-2)
also showed this sequence variant. As expected for an X-
linked mode of inheritance, the mother was heterozygous
for this substitution, whereas the father did not carry this
sequence variation (data not shown). Thus, we conclude
that this CACNA1F sequence variant is not itself disease
causing but that it may modify the phenotype. Alterna-
tively, the CACNA1F substitution represents a rare poly-
morphism not yet described.
To determine the underlying pathogenic effect of the
deletion mutation, we investigated two alternatives. The
wild-type sequence of CABP4 comprises a duplicate AG
dinucleotide at the junction of intron 5 and exon 6:
-tctctcccgcagAGTTTGTGAT. The 2-bp–deletion mutation
removes one of these AG dinucleotides and, thus, might
cause a translational frameshift and/or affect transcript
splicing by altering the acceptor site. To distinguish these
two possibilities, we performed a computational search for
potential splice–donor/acceptor sites within reasonable vi-
cinity of the mutation. The normal splice acceptor -tctctc-
ccgcagAGTTTGTGAT was given a score of 0.98, whereas,
for the splice acceptor with a deletion of one AG, -tctctcc-
cgcAGTTTGTGAT, a slightly reduced score of 0.90 was cal-
culated (score 0.0–1.0 reﬂects increasing splice-site efﬁ-
ciency). We interpreted these ﬁndings to mean that the
deletion of one of the two tandem AG nucleotides may
not dramatically alter splicing efﬁciency. To test these pre-
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Figure 3. ERG proﬁle of the patients with CSNB investigated. A–D, Full-ﬁeld ERG of family A. Results of an unaffected representative
subject are shown in the left column. Results from patients II-5 and II-6 are shown in the middle and right columns, respectively. The
upper line represents the right eye, the lower line the left eye. A, Scotopic ISCEV standard ﬂash (2.5 candelas [cd]/m2) attenuated by
24 dB. Moderately decreased amplitude and delayed culmination time of the b-wave were present in both patients. B, Scotopic standard
ﬂash. Normal a-wave amplitude and implicit time with an absent b-wave (negative ERG) was present in both patients. C, Photopic
ISCEV standard ﬂash (30 cd/m2). Decreased amplitude of both a- and b-waves with normal implicit times was present in both patients.
D, Photopic 30-Hz ﬂicker stimulus. Decreased b-wave amplitude with normal implicit time was present in both patients. E, Full-ﬁeld
ERG of index patient of family B. OD p right eye; OS p left eye. Top panel, Scotopic ERG. Uppermost trace indicates ERG elicited by
ISCEV standard ﬂash (2.5 cd/m2) attenuated by 24 dB, with highly decreased amplitude and delayed culmination time of the b-wave
(3 and 9 ms above upper norm for OD and OS, respectively). Middle trace indicates unattenuated scotopic ISCEV standard ﬂash, with
normal a-wave amplitude and implicit time with an absent b-wave (negative ERG). Lower trace indicates a repeat of the same conditions
as used in the second trace. Bottom panel, Photopic ERG. Upper trace indicates white background light (30 cd/m2) with ISCEV standard
ﬂash stimulus and decreased amplitude of both a- and b-waves with delayed implicit time 3 ms above upper norm value; the wavelets
toward the end of this trace are blink artifacts in both eyes. Lower trace indicates photopic 30-Hz ﬂicker stimulus with highly decreased
amplitude and normal implicit time.
dictions, we performed RT-PCR experiments. As reported
in the literature, CABP4 transcripts had been detectedonly
in retina.29 Here, we were able to show expression of
CABP4 also in peripheral blood, using RT-PCRexperiments
(ﬁg. 5).
Sequence analyses of cloned RT-PCR products revealed
the deletion of the AG dinucleotide in the transcripts of
patient II-5 in family A, whereas the AG sequence was
present in the control. Analysis of four clones from the
RT-PCR product of the mother also showed the presence
of the AG dinucleotide. Sequencing of RT-PCR products
from patient II-1 of family B conﬁrmed the presence of
mutant (T) and wild-type (C) alleles at position c.370.
Primers in exons 2 and 6, where the reverse primer is
positioned downstream of the deletion mutation in exon
6, yielded a speciﬁc fragment of the expected size (581
bp) from control cDNA templates (ﬁg. 5B), and sequence
analysis conﬁrmed its identity (data not shown). A frag-
ment of the same size was also obtained from the cDNA
of the unaffected mother (I-2) of family A (ﬁg. 2A), her
affected son (II-5) (ﬁg. 2A), and the compound hetero-
zygous patient (II-1) of family B (ﬁg. 2B). Using primers
in exons 2 and 4 revealed similar results (ﬁg. 5C). A CSNB-
unrelated gene, CSPG2, was used as a control (ﬁg. 5D).
Ampliﬁcation of only these RT-PCR products indicates
that no aberrant splice variants accumulate, although the
abundance of patients’ transcripts was extremely low. In
the case of the amplicon covering exons 2–6, the expected
product was very weak and difﬁcult to visualize (ﬁg. 5B).
Taken together, the RT-PCR experiments do not indicate
that the homozygous deletion (c.800_801delAG) or com-
pound heterozygous mutation (c.800_801delAG and
c.370CrT) causes aberrant splicing of CABP4. To compare
the transcript levels in cDNA from an unaffected control,
from the mother I-2 and the patient II-5 of family A, and
from the patient II-1 of family B, we performed real-time
quantitative RT-PCR (TaqMan) experiments with a
TaqMan probe spanning exons 2 and 3. In comparison to
the control (set to 100%), the heterozygous mother of
family A (I-2) (ﬁg. 2A) did not show a statistically signif-
icant reduction, although a tendency may be indicative
(ﬁg. 5E). In contrast, both affected patients (II-5 from fam-
ily A and II-1 from family B) showed a statistically signif-
icant reduction of 60%–70%, compared with the control
(ﬁg. 5E).
Discussion
Ten of our patients with the CSNB2 phenotype do not
carry mutations in CACNA1F. To search for molecular de-
fects in these patients, we began to investigate the poten-
tial role of other factors that are involved in the signal
transduction pathway from photoreceptors to adjacent bi-
polar cells. CABP4 is one such candidate, since mice lack-
ing functional Cabp4 show a phenotype similar to that
observed in patients with CSNB2 and with CACNA1F
mutations.
Here, we were able to identify two different mutations
(c.800_801delAG and c.370CrT) in the CABP4 gene in
two families with a phenotype of CSNB2. Interestingly,
the deletion c.800_801delAG segregates in both families.
On the basis of haplotype reconstruction and the Swiss
ancestry of both families, a common origin of this mu-
tation in all three apparently unrelated individuals is
possible.
With RT-PCR experiments, we were able to show that
CABP4 is expressed in peripheral blood, althoughprevious
studies revealed a retina-speciﬁc expression in human and
mouse, based on northern blot and RT-PCR analyses, re-
spectively.29 The different results observed may be ex-
plained by the low abundance of CABP4 transcript in
blood. Detection required large amounts of cDNA, 35#
ampliﬁcation cycles, and loading of the entire volume to
an agarose gel. In the previous study, expression of the
human gene was analyzed only by northern blot hybrid-
ization, a method less sensitive than RT-PCR. The expres-
sion of the mouse gene was analyzed with RT-PCR exper-
iments. However, cDNA synthesized from blood RNA was
not used as a template, and the expression in human and
mouse may also vary.29
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Figure 4. Sequence alignment of normal CABP4 protein and the two mutant variants. Gray boxes indicate the four predicted Ca2-
binding EF hand motifs; however, EF2 was predicted to be nonfunctional.29 Red letters show the mutated amino acids and the elongated
residues. The missense mutation is marked by an arrow. Bold letters highlight known and predicted phosphorylation sites.
RT-PCR experiments revealed that the homozygous de-
letion still yields spliced transcripts, albeit at reduced
abundance in comparison with control samples and the
heterozygous unaffectedmother. Interestingly, lower tran-
script levels have also been found in the affected patient
of family B, who carries the deletion allele and a missense
mutation on the second allele. Recently, it has been shown
that missense mutations in Cav1.4a can not only inﬂu-
ence the gating properties of the L-type Ca2 channel but
can also lead to a reduced protein level.38 Similarly to this
example of Cav1.4a, our data suggest that the substitution
c.370CrT in our patient may also lead to reduced levels
of CABP4 transcripts. The residual amount, 30%–40%, of
CABP4 transcripts may explain CSNB2. Even though the
scotopic and photopic b-waves and the 30-Hz ﬂicker ERG
are reduced, the remaining CABP4 transcript may also re-
sult in a low amount of functional proteins, and, thus,
signaling is not completely blocked. A possible explana-
tion for the lower expression may be a reduced splicing
efﬁciency, since the deletion altered the context of the
splice-acceptor sequence. Additionally, the amino acid
substitution (p.Arg124Cys) may also impact the splicema-
chinery, for example, because of the insertion of a novel
exon-splicing–enhancer binding site by this substitution.
Discovering whether our observations also apply to the
retina will require the investigation of affected human
retinae.
The c.800_801delAG mutation is predicted to cause a
frameshift, p.Glu267fs, which elongates the protein by 91
novel amino acids (ﬁg. 4). Whereas the ﬁrst of these novel
amino acids affects only the last residue of one of theCa2-
bindingmotifs (EF4) and, thus, probably does not interfere
with this function, the tertiary structure of the extended
proteinmay impair the Ca2-binding afﬁnity and capacity.
The other mutation, p.Arg124Cys, is located upstream of
the ﬁrst EF motif, and, thus, Ca2 binding seems to not
be affected.
Changes in protein structure can alter the interaction
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Figure 5. CABP4 transcript analysis. A, Structure of the CABP4 gene. Boxed symbols represent exons; lines represent introns. Arrows
indicate the position of primers used for RT-PCR experiments; the caret indicates the position of the TaqMan probe; dotted lines indicate
two mutations in CABP4, c.370CrT and c.800_801delAG. B–D, Ethidium bromide– and GelRed-stained agarose gels with RT-PCR fragments.
B, Primers from CABP4 exons 2 and 6. C, Primers from CABP4 exons 2 and 4. D, Primers from CSPG2 exons 6 and 9. E, Relative expression
of CABP4 transcripts from quantitative real-time RT-PCR experiments with the use of TaqMan probes. Threshold-cycle values ranged from
19 to 22 for samples probed with 18S rRNA and from 29 to 33 for samples probed with CABP4. Bars represent CIs; .Pp .05
with other proteins, inﬂuence their intracellular locali-
zation, andmodify their enzymatic activity and/or protein
stability by diverse mechanisms. Recently, it has been
shown that CABP4 interacts with a cytoplasmic fragment
of Cav1.4a (aa residues 1445–1983).29 Whether the ex-
tended CABP4 protein or the amino acid substitution al-
ters the interaction with Cav1.4a needs to be tested.
Another possiblemechanism thatmay result in unstable
CABP4 protein level is posttranslational modiﬁcations,
like phosphorylation of the extended protein. Five novel
potential phosphorylation sites are contained within the
protein extension. However, it is very likely that the elon-
gated CABP4 protein gets misfolded and, thus, becomes
subject to degradation. In summary, in our attempt to
understand the complex regulation of nocturnal vision,
we have identiﬁed yet another protein, CABP4, that is
important in this signal transduction pathway.
In humans and mice, mutations in CABP4 lead to a
signaling defect from rods and cones to bipolar cells. The
photoreceptor synapses in Cabp4-deﬁcient mice were se-
verely disrupted, as shown by the thinning of the OPL, a
reduction in the number of synaptic ribbons and photo-
receptor terminals, and the deﬂation of rod spherules and
cone pedicles. The absence of Cabp4 also resulted in the
formation of ectopic synapses between rods and rod bi-
polar or horizontal cells in the ONL. To our knowledge,
such changes have not yet been described for the human
CSNB type and would be better suited to a progressive
retinal disease like a cone-rod dystrophy. The severity of
the mouse phenotype may be caused by the different type
of the mutations. So far, only three patients have been
described as showing mutations in CABP4, and data from
additional patients carrying mutations in this gene are
needed to get a more detailed picture about the pheno-
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type-genotype correlation. However, similar phenotypic
differences in human and mice have been described for
patients carrying CACNA1F mutations and for mice lack-
ing Cacna1f.31 Interestingly, patients II-5 and II-6 of family
A did not complain about night blindness. The disease
course was investigated in the index patient, II-5. After
CSNB was diagnosed, the disease was stationary over the
following 30 years, after which he experienced decreased
VA and photophobia. Hence, at least for this patient, a
progressive course of the disease seems possible. This as-
pect still needs to be followed up for patient II-1 from
family B and for other patients with novel CABP4 muta-
tions. Compared with CACNA1F, CABP4 is a small gene
that can be screened rapidly for mutations in the DNA of
patients with CSNB2 and, hence, represents a valuable
candidate in diagnostic approaches. This is also of im-
portance since, to date, patients carrying CACNA1F or
CABP4 mutations cannot be clinically distinguished, in
contrast to patients carrying NYX and GRM6 mutations.20
Mutations in CABP4 and in additional genes implicated
in nocturnal vision will help unravel the complexity of
signaling from the photoreceptors to the adjacent second-
order neurons.
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